open access
Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas
, 1, 21, 1, 1, 1, 21
Affiliations- Department of Obstetrics and Gynecology, the Affiliated Hospital of Qingdao University, Qingdao, China
- Qingdao University, Qingdao, China, China
open access
Abstract
Objectives: To compare the clinical characteristics and prognosis of women with clear cell versus high-grade serous ovarian carcinoma. Material and methods: Retrospective analysis of the clinical data of 50 cases patients with ovarian clear cell carcinoma (OCCC) and 103 cases with high-grade serous ovarian carcinoma (HGSOC), who were initially treated and completed standardized therapy in Affiliated Hospital of Qingdao University from January 2013 to December 2017. Results: There were significant differences in age, gravidity (G > 1), chief complaint, with ovarian endometriosis, tumor diameter, unilateral or bilateral, cystic and solid tumor, CA125, HE4, CA199, lactate dehydrogenase (LDH), and FIGO stage between the two groups. The differences in the prognosis between OCCC patients and HGSOC patients with early stage (FIGO I–II) were not statistically significant. The 5-year overall survival and progression-free survival of OCCC patients were significantly worse than those of HGSOC patients with advanced stage (FIGO III–IV) (p < 0.05). FIGO stage and non-R0 resection were independent risk factors affecting the prognosis of patients with ovarian clear cell carcinoma, screening by Cox regression analysis. FIGO stage, the lowest value of CA125, and non-R0 resection were independent risk factors affecting the prognosis of patients with high-grade serous ovarian cancer. Conclusions: The clinical characteristics and prognosis of OCCC are different from those of HGSOC. Ovarian clear cell carcinoma (OCCC) patients have a significantly worse prognosis than those with HGSOC in the advanced stage (FIGO Ⅲ–Ⅳ). Satisfactory tumor resection is an essential factor related to the prognosis of patients with OCCC and HGSOC.
Abstract
Objectives: To compare the clinical characteristics and prognosis of women with clear cell versus high-grade serous ovarian carcinoma. Material and methods: Retrospective analysis of the clinical data of 50 cases patients with ovarian clear cell carcinoma (OCCC) and 103 cases with high-grade serous ovarian carcinoma (HGSOC), who were initially treated and completed standardized therapy in Affiliated Hospital of Qingdao University from January 2013 to December 2017. Results: There were significant differences in age, gravidity (G > 1), chief complaint, with ovarian endometriosis, tumor diameter, unilateral or bilateral, cystic and solid tumor, CA125, HE4, CA199, lactate dehydrogenase (LDH), and FIGO stage between the two groups. The differences in the prognosis between OCCC patients and HGSOC patients with early stage (FIGO I–II) were not statistically significant. The 5-year overall survival and progression-free survival of OCCC patients were significantly worse than those of HGSOC patients with advanced stage (FIGO III–IV) (p < 0.05). FIGO stage and non-R0 resection were independent risk factors affecting the prognosis of patients with ovarian clear cell carcinoma, screening by Cox regression analysis. FIGO stage, the lowest value of CA125, and non-R0 resection were independent risk factors affecting the prognosis of patients with high-grade serous ovarian cancer. Conclusions: The clinical characteristics and prognosis of OCCC are different from those of HGSOC. Ovarian clear cell carcinoma (OCCC) patients have a significantly worse prognosis than those with HGSOC in the advanced stage (FIGO Ⅲ–Ⅳ). Satisfactory tumor resection is an essential factor related to the prognosis of patients with OCCC and HGSOC.
Keywords
ovarian clear cell carcinoma; high-grade serous ovarian carcinoma; prognosis; risk factors; clinical characteristics
Supp./Additional Files (1)
About this articleTitle
Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas
Journal
Issue
Article type
Research paper
Pages
792-798
Published online
2022-12-06
Page views
598
Article views/downloads
529
DOI
Pubmed
Bibliographic record
Ginekol Pol 2023;94(10):792-798.
Keywords
ovarian clear cell carcinoma
high-grade serous ovarian carcinoma
prognosis
risk factors
clinical characteristics
Authors
Shixiang Dong
Fengsheng Yu
Yutong Liu
Xiao Yu
Xin Sun
Wenjie Wang
Yankui Wang
References (22)- Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi, (Chinese). 2014; 43(10): 649–650.
- Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998; 70(2): 255–258.
- Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000; 92(18): 1534–1535.
- Oliver KE, Brady WE, Birrer M, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017; 147(2): 243–249.
- Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008; 109(3): 370–376.
- Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989; 35(2): 199–203.
- Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer . Obstetrics & Gynecology. 1990; 72(2): 263–273.
- Kennedy AW, Markman M, Biscotti CV, et al. Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol. 1999; 74(1): 108–114.
- Leitao MM, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004; 28(2): 147–159.
- Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006; 102(2): 285–291.
- Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989; 32(1): 65–71.
- Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997; 176(3): 572–579.
- King CM, Barbara C, Prentice A, et al. Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. J Pathol. 2016; 238(2): 185–196.
- Park JY, Kim DY, Suh DS, et al. Significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma. Int J Gynecol Cancer. 2018; 28(1): 11–18.
- Kim HS, Choi HY, Lee M, et al. Systemic inflammatory response markers and CA-125 levels in ovarian clear cell carcinoma: a two center cohort study. Cancer Res Treat. 2016; 48(1): 250–258.
- Nakagawa N, Koda H, Nitta N, et al. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. Acta Med Okayama. 2015; 69(4): 227–235.
- Zhu J, Jiang L, Wen H, et al. Prognostic value of serum CA19-9 and perioperative CA-125 levels in ovarian clear cell carcinoma. Int J Gynecol Cancer. 2018; 28(6): 1108–1116.
- Fujino T, Watanabe T, Yamaguchi K, et al. The development of hypercalcemia in a patient with an ovarian tumor producing parathyroid hormone-related protein. Cancer. 2015; 70(12): 2845–2850, doi: 10.1002/1097-0142(19921215)70:12<2845::aid-cncr2820701221>3.0.co;2-f.
- Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996; 60(3): 412–417.
- Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(24): 3621–3627.
- Duska LR, Garrett L, Henretta M, et al. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010; 116(3): 374–377.
- Nasioudis D, Mastroyannis SA, Albright BB, et al. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. Gynecol Oncol. 2018; 150(1): 14–18.
